Chronic Pain Susceptibility and Your Genetics

Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder

Reviewed by ExomeDNA Editorial Process · [/methodology/editorial-process]

Last reviewed: 2026-05-29

DISCLAIMER: This content is educational and informational. For health decisions, consult a clinician.

Chronic pain is defined as persistent pain lasting beyond the expected period of tissue healing, typically three months or more. It affects an estimated one in five adults globally and involves changes in how the central nervous system processes pain signals — a process researchers call central sensitization. Genome-wide research has now identified dozens of genetic loci associated with chronic pain phenotypes, pointing toward specific biological pathways. This page explores what those findings mean and how they fit into the broader biology of pain.

What is chronic pain susceptibility?

Chronic pain susceptibility refers to inter-individual variation in the likelihood that persistent, ongoing pain will develop or intensify over time. Unlike acute pain, which serves as a protective warning signal, chronic pain reflects alterations in pain-processing circuits that can persist well beyond any initial tissue damage. These alterations involve both peripheral sensory neurons and central nervous system structures, including the spinal cord and brain regions that modulate pain perception. Susceptibility varies widely across individuals — a gap that genetics, among other factors, helps explain.

The genetics behind chronic pain susceptibility

A large-scale genome-wide association study of UK Biobank participants identified multiple genomic loci linked to chronic pain traits using a confirmatory factor analysis approach to capture shared genetic architecture across pain sites^[1]. The top candidate gene from that work, ranked by locus-to-gene (L2G) modeling from the Open Targets Platform, is IRAG1 (chromosome 11), a protein involved in calcium signaling in smooth muscle and potentially in neuronal excitability pathways. Close behind is TSPAN2 (chromosome 1), a tetraspanin family member expressed in oligodendrocytes and implicated in nerve myelination — the insulation process that governs how efficiently electrical signals travel along nerve fibers.

Perhaps the most biologically compelling finding in this dataset is the association near TRPM8 on chromosome 2. TRPM8 encodes a transient receptor potential ion channel found in sensory neurons; it is one of the primary molecular sensors for cold temperature and cooling compounds. Its presence among the top chronic pain loci provides a direct mechanistic bridge between peripheral sensory biology and pain susceptibility. Variants near TRPM8 achieve a high L2G confidence score (0.83), making it one of the stronger gene-level signals in this study.

The gene NGF, encoding nerve growth factor, also appears in this dataset alongside its chromosomal neighbor TSPAN2. Nerve growth factor is a well-studied mediator of inflammatory and nociceptive pain; elevated NGF signaling has been linked to sensitization of pain-detecting neurons in multiple contexts. Its genetic association with chronic pain phenotypes adds further plausibility to the biological story this locus tells.

Additional candidate genes in the L2G ranking include FHL5 (chromosome 6), a transcriptional co-activator; PRDM16 (chromosome 1), a transcription factor with roles in cell fate and metabolic regulation; PHACTR1 (chromosome 6), which modulates phosphatase and actin cytoskeleton dynamics in endothelial and neuronal cells; LRP1 (chromosome 12), a broad endocytic receptor involved in neuroprotective signaling; and IL6R (chromosome 1), the receptor for interleukin-6 — a cytokine central to inflammatory pain amplification. The IL6R signal is particularly noteworthy given the known role of inflammatory cytokines in pain sensitization.

The MEF2D transcription factor (chromosome 1) and ITPK1 (chromosome 14), an enzyme in inositol phosphate metabolism, round out the higher-confidence tier. Collectively, these loci implicate neuronal excitability, myelination, inflammatory signaling, and calcium-dependent processes as the core biological axes of genetic chronic pain susceptibility.

32 genetic loci were identified in the top-ranked gene mapping for this chronic pain phenotype dataset, with L2G confidence scores ranging from 0.06 to 0.86 across candidate genes (Open Targets Platform, accessed 2026-05-29).

What the research says

The primary evidence base for this trait comes from a 2024 genome-wide association study by Carey and colleagues, published in Nature Human Behaviour, which used confirmatory factor analysis to distill structured chronic pain signals from UK Biobank phenotype data^[1]. This methodological approach — applying factor analysis to identify latent pain dimensions across multiple body sites — is more refined than single-site pain GWAS designs. The result is a set of loci that appear to reflect shared biological mechanisms underlying chronic pain broadly, rather than site-specific factors like localized injury.

It is important to note that this is a single large study rather than a replicated meta-analysis, and therefore findings should be interpreted with appropriate hedging. The research suggests, rather than confirms, that these genetic variants contribute meaningfully to chronic pain susceptibility. Effect sizes for individual variants are modest — consistent with the polygenic architecture expected for a complex pain trait.

Complementing the GWAS evidence, ClinVar contains 228 pathogenic and 243 likely-pathogenic variant entries across genes implicated in this region, including ASTN2, FGF23, LRP1, PHACTR1, and PRDM16, though these ClinVar entries predominantly reflect rare monogenic conditions rather than the common-variant chronic pain associations identified here. The presence of PHACTR1 and LRP1 in both sets suggests these genes operate across a spectrum from rare disease to common-trait biology.

1 in 5 adults globally are estimated to experience chronic pain, making it one of the most prevalent conditions in which genetic architecture research carries meaningful public health implications (global epidemiological estimates, general literature).

How chronic pain susceptibility affects you

Elevated genetic susceptibility for chronic pain does not mean someone will experience persistent pain. It means the biological systems that regulate pain processing may be calibrated somewhat differently at baseline — a difference that can interact with life events, physical health, sleep quality, stress exposure, and inflammation levels to influence outcomes over time.

The gene candidates implicated here point to three overlapping biological axes. First, peripheral sensitization: genes like TRPM8 and NGF affect the sensitivity and signaling capacity of the sensory neurons that first detect potentially damaging stimuli. When these neurons become sensitized, normally innocuous inputs can register as painful. Second, central processing and myelination: TSPAN2's role in nerve insulation suggests that altered signal conduction efficiency in the central nervous system may be part of the susceptibility picture. Third, inflammatory amplification: IL6R and PHACTR1 suggest that how strongly the inflammatory system amplifies pain signals following injury or stress may itself be genetically modulated.

For people who carry variants associated with elevated susceptibility, understanding this biological backdrop can support more informed conversations with clinicians and more targeted attention to the modifiable factors that interact with these pathways.

Working with your chronic pain susceptibility profile

General health research — independent of any genetic finding — consistently identifies several behavioral domains as relevant to pain regulation. These are broad health literacy points, not personalized clinical recommendations.

Physical activity has one of the strongest evidence bases in general pain research. Regular aerobic exercise and progressive resistance training are associated with modulation of central pain-processing pathways, including endogenous opioid and endocannabinoid systems. The effect appears dose-dependent and does not require intense exertion.

Sleep quality is deeply intertwined with pain regulation. Disrupted or insufficient sleep has been shown to lower pain thresholds and amplify the subjective intensity of pain experiences in experimental research. Addressing sleep hygiene is therefore relevant for anyone with heightened interest in pain biology.

Mind-body approaches — including cognitive behavioral strategies, mindfulness-based stress reduction, and pain-specific psychological interventions — have demonstrated measurable effects on chronic pain outcomes in randomized controlled trial evidence. These approaches target the central processing dimension of pain, which the genetic evidence here suggests may be a core susceptibility axis.

Inflammatory load is modulated by diet, stress, and metabolic health. Given the IL6R and PHACTR1 signals in this dataset, there is biological plausibility for the general recommendation to support anti-inflammatory dietary patterns and stress management as part of long-term pain health maintenance.

Anyone with clinical concerns about pain should consult a qualified healthcare provider. ExomeDNA's genetic reports are wellness tools that support health literacy, not substitutes for clinical evaluation.

Related traits and genes

Chronic pain susceptibility overlaps biologically with several adjacent traits available on the ExomeDNA platform. Fibromyalgia risk and pain sensitivity share candidate genes and central sensitization mechanisms with this trait. Neuropathic pain susceptibility focuses more specifically on peripheral nerve dysfunction pathways.

From a systemic biology perspective, inflammatory response is directly relevant — the IL6R locus links chronic pain susceptibility to the same cytokine signaling axis covered in that trait. Sleep quality is another important cross-category connection, given the bidirectional relationship between sleep disruption and pain amplification.

For deeper gene-level information, the TRPM8 gene page covers this ion channel's role in temperature and pain sensing in greater detail.

Frequently asked questions

Can a genetic test tell me whether I will develop chronic pain?

No genetic test can predict with certainty whether someone will develop chronic pain. Genetics is one of many contributing factors, alongside injury history, stress, sleep patterns, and overall health. Variants identified in genome-wide studies reflect population-level associations, not individual destiny. An ExomeDNA genetic report is a wellness product designed to support health literacy, not a clinical assessment tool. People with elevated genetic susceptibility scores may never experience persistent pain, while people without them sometimes do.

What does the TRPM8 gene have to do with pain?

TRPM8 encodes a temperature-sensitive ion channel found in sensory neurons. It responds to cool temperatures and certain chemical signals, and it plays a well-documented role in cold-evoked pain perception. Genome-wide research has identified variants near TRPM8 that associate with chronic pain phenotypes, making it one of the more biologically plausible candidate genes in this space. Research on its precise contribution to persistent everyday pain is ongoing.

What role does NGF play in chronic pain biology?

Nerve growth factor, encoded by the NGF gene, is a signaling protein that supports the survival and function of sensory neurons. It is also involved in inflammatory pain sensitization — elevated NGF signaling has been studied in conditions involving musculoskeletal and neuropathic discomfort. Genome-wide association research has identified a signal near NGF and its neighbor TSPAN2 on chromosome 1, suggesting this region may contribute to inter-individual variation in pain susceptibility, though the effect size from any single variant is modest.

Is chronic pain more genetic or environmental?

Chronic pain arises from an interplay between genetics, environment, psychology, and biology. Twin studies have estimated the heritability of chronic pain phenotypes at roughly 30 to 50 percent for some conditions, indicating that genetics plays a meaningful but not dominant role. Environmental exposures such as physical injury, prolonged stress, poor sleep, and inflammation can all shift pain processing independently of genetic background. Genome-wide research continues to map common variants that collectively contribute to the genetic portion of this variation.

What lifestyle factors support healthy pain regulation?

General health research consistently links several modifiable behaviors to better pain regulation outcomes. Regular aerobic and resistance exercise has been shown to modulate central pain-processing pathways. Prioritizing sleep quality matters because sleep disruption amplifies pain sensitivity. Mind-body practices such as cognitive behavioral strategies and mindfulness have demonstrated measurable effects on chronic pain experience in clinical research. Reducing systemic inflammation through dietary patterns and stress management may also support overall nervous system resilience. These are general health literacy points, not personalized recommendations — a clinician is the appropriate source for individualized guidance.

References

1. Carey et al. (2024). Principled distillation of UK Biobank phenotype data reveals underlying structure in human variation. Nature Human Behaviour. PMID: 38965376.

Data sources:

• GWAS Catalog (NHGRI-EBI, accessed 2026-05-29)
• Open Targets Platform (CC0 1.0, accessed 2026-05-29)
• ClinVar (NCBI, accessed 2026-05-29) — entries at ≥2-star review status
• ClinGen Gene-Disease Validity (CC0 1.0, accessed 2026-05-29)

By the ExomeDNA Research Team

FDA wellness compliance statement: This content is intended for educational and informational purposes only. ExomeDNA's genetic reports are wellness products, not clinical tools, and are not substitutes for professional health guidance. Genetic variants discussed reflect population-level associations from published research. Individual genetic results should be interpreted with the guidance of a qualified healthcare provider.